Curated News
By: NewsRamp Editorial Staff
April 29, 2026

Lantern Pharma Expands predictBBB Platform into Large Quantitative Model

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Lantern Pharma's predictBBB platform expansion into LQM gives researchers a competitive edge with real-time molecular intelligence for drug discovery.
  • The platform uses RADR AI to analyze physicochemical properties, drug-likeness, structure, and topology from a single SMILES input for rapid profiling.
  • By broadening access to advanced computational tools, Lantern Pharma accelerates development of targeted cancer therapies, improving patient outcomes.
  • Single SMILES input now generates comprehensive developability profiles, turning complex molecular analysis into a simple web-based query.

Impact - Why it Matters

This expansion matters because it democratizes access to advanced AI-driven drug discovery tools, enabling researchers worldwide to rapidly evaluate small molecules and potentially accelerate the development of new cancer therapies. By integrating molecular intelligence into a user-friendly web platform, Lantern Pharma is lowering barriers to computational drug design, which could lead to faster identification of promising drug candidates and more efficient use of resources in oncology R&D.

Summary

Lantern Pharma (NASDAQ: LTRN) has unveiled a significant expansion of its predictBBB™ platform into a Large Quantitative Model (LQM), creating a real-time, web-based molecular intelligence engine. This new tool allows researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. By leveraging Lantern’s proprietary RADR® AI technology, the platform delivers rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture, and topological mapping, with benchmark-validated performance. The enhanced platform is designed to streamline drug discovery workflows and broaden access to advanced computational tools, potentially accelerating the development of new therapeutics.

Lantern Pharma is a clinical-stage precision oncology company that uses AI and machine learning to transform cancer therapy development. Its clinical pipeline includes promising candidates such as LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned subsidiary. The company also offers withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research platform, representing a new revenue stream. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.

This news was disseminated by MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. MissionIR focuses on enhancing visibility for private and public companies within the investment community through syndicated content, press release enhancement, and social media distribution. The platform provides access to a vast network of wire solutions via InvestorWire and editorial syndication to over 5,000 outlets, ensuring maximum impact for corporate communications.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Expands predictBBB Platform into Large Quantitative Model

blockchain registration record for this content.